05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
21:52 , Dec 1, 2017 |  BC Week In Review  |  Company News

ArcherDX to develop companion diagnostic for CC-122

ArcherDx Inc. (Boulder, Colo.) will develop and commercialize a companion diagnostic to identify diffuse B cell lymphoma patients who may best respond to CC-122 from Celgene Corp. (NASDAQ:CELG). CC-122 is a cancer pleiotropic pathway modifier...
23:34 , Nov 2, 2017 |  BC Innovations  |  Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
04:00 , Oct 28, 2017 |  BioCentury  |  Product Development

Chinks in the armor

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since...
20:21 , Jul 7, 2017 |  BC Week In Review  |  Company News

BeiGene grants Celgene PD-1 rights, acquires China operations

BeiGene Ltd. (NASDAQ:BGNE) granted Celgene Corp. (NASDAQ:CELG) exclusive rights in most of the world to its PD-1 inhibitor BGB-A317 for non-hematological indications and acquired Celgene's commercial operations in China, including local rights to a handful...
00:22 , Jul 7, 2017 |  BC Extra  |  Company News

BeiGene grants Celgene PD-1 rights, acquires China operations

BeiGene Ltd. (NASDAQ:BGNE) granted Celgene Corp. (NASDAQ:CELG) exclusive rights in most of the world to its PD-1 inhibitor BGB-A317 for non-hematological indications and acquired Celgene's commercial operations in China, including local rights to a handful...
07:00 , Apr 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: An undetermined target

Cancer INDICATION: Multiple myeloma (MM); hematologic malignancies Cell culture and mouse studies suggest a deuterium-containing enantiomer of the racemic compound CC-122 could help treat MM and other hematologic malignancies more effectively than CC-122. Chemical synthesis...
07:00 , Apr 2, 2015 |  BC Innovations  |  Translation in Brief

Mirror, mirror

DeuteRx LLC has developed a method for stabilizing and selecting individual enantiomers of drugs prone to forming racemic mixtures by replacing the hydrogen atom at the swivel point with deuterium. Using the technology, the company...